Cite
HARVARD Citation
Uccelli, A. et al. (2021). Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. Lancet neurology. 20 (11), pp. 917-929. [Online].